Floatz logo

Idarubicine

Chronic Myeloid Leukemia

M.D. Anderson Cancer CenterPhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

85 Active assets in the Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB
METHOTREXATE
M.D. Anderson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →